<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal actions of dopamine</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal actions of dopamine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal actions of dopamine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> is synthesized within the kidney in the proximal tubule from circulating L-dopa, via the enzyme L-amino acid decarboxylase [<a href="#rid1">1-3</a>]. There are also renal nerves that contain dopamine, although the physiologic significance of these nerves is unclear.</p><p>The renal actions of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> are discussed here. The use of dopamine in patients with shock is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RENAL ACTIONS</span><span class="headingEndMark"> — </span>Circulating and locally formed <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> can affect both sodium excretion and renal hemodynamics via activation of the D1-like and D2-like receptors [<a href="#rid1">1,4,5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Natriuresis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> is a natriuretic hormone, increasing sodium excretion by diminishing reabsorption, primarily in the proximal tubule [<a href="#rid1">1,2,6,7</a>]. This effect of dopamine appears to involve both of the steps involved in transtubular sodium transport:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a>, acting via the generation of cyclic AMP, decreases the activity of the Na-H exchanger in the luminal membrane, a transporter that plays an important role in the entry of filtered sodium into the cell [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> inhibits the Na-K-ATPase pump in the basolateral membrane [<a href="#rid1">1,2,8</a>]. Sodium that has entered the cell from the lumen is normally transported by this pump out of the cell into the peritubular interstitium (and then the peritubular capillary).</p><p></p><p>In addition to these proximal effects, <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> can also reduce sodium reabsorption in the collecting tubules. This response may be mediated both by decreased secretion of aldosterone [<a href="#rid9">9</a>] and by diminished activity of the Na-K-ATPase pump in the renal tubular cells [<a href="#rid10">10</a>]. The latter effect appears to be mediated by local prostaglandin generation [<a href="#rid10">10</a>].</p><p>The natriuretic effects of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> depend in part upon dietary sodium intake. During dietary sodium restriction, the ability of endogenous renal dopamine to inhibit sodium transport is abolished. In addition, intravenous dopamine or <a class="drug drug_general" data-topicid="8629" href="/d/drug information/8629.html" rel="external">fenoldopam</a> (a DA1 receptor agonist) induces natriuresis in subjects consuming a high-sodium diet but not a low-sodium diet. However, administration of an angiotensin-converting enzyme (ACE) inhibitor to individuals on a low-sodium diet restores the natriuretic properties of dopamine, suggesting an interaction between dopamine and the renin-angiotensin system [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Vascular effects</span><span class="headingEndMark"> — </span>Parenteral <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> has an onset of action within 5 minutes, an elimination half-life of 2 minutes, and, after it is discontinued, a duration of action of less than 10 minutes; varying doses of dopamine have different pharmacodynamic effects [<a href="#rid12">12</a>]. When infused in low doses (0.5 to 2 mcg/kg per minute), dopamine primarily stimulates dopaminergic receptors (DA1 and DA2) in the renal vascular beds, which dilates the interlobular arteries and both the afferent (preglomerular) and efferent (postglomerular) arterioles [<a href="#rid6">6,12,13</a>]. The net effect is a relatively large increase in renal blood flow with a lesser or no elevation in glomerular filtration rate (GFR) [<a href="#rid7">7,14</a>]; the relative lack of increase in GFR is due to the efferent dilatation, which minimizes the rise in intraglomerular pressure. At intermediate doses (2 to 5 mg/kg/min), beta receptors are stimulated, primarily in the myocardium, and norepinephrine is released from sympathetic neurons, increasing heart rate and cardiac output [<a href="#rid12">12</a>]. At higher concentrations (above 5 mcg/kg per minute), dopamine induces renal vasoconstriction, a response that is mediated by activation of the alpha-adrenergic receptors [<a href="#rid6">6,12,13,15</a>].</p><p>The increase in kidney perfusion with low-dose <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> may not be seen in patients with acute tubular necrosis (ATN) [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Physiologic role</span><span class="headingEndMark"> — </span>Although these actions can be readily demonstrated by intravenous infusion [<a href="#rid7">7</a>], the physiologic importance of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> remains to be defined. The local production of dopamine is increased by volume expansion [<a href="#rid7">7,16</a>], a finding that is consistent with a role in the ensuing natriuresis. This response is mediated in part by increased activity of L-amino acid decarboxylase, the enzyme that converts L-dopa into dopamine [<a href="#rid2">2</a>]. Also compatible with dopamine being a natriuretic hormone is the observation that administration of a dopamine receptor inhibitor to experimental animals impairs the response to modest volume expansion [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL UTILITY</span></p><p class="headingAnchor" id="H7"><span class="h2">Postischemic acute tubular necrosis</span><span class="headingEndMark"> — </span>The previously mentioned findings have led to the use of low-dose (ie, "renal dose") <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> both to increase the urine output and to preserve kidney function in oliguric patients at risk for postischemic acute tubular necrosis (ATN). However, such therapy is ineffective and may cause harm, and therefore should <strong>not</strong> be used. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Polyuria</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> is frequently administered to maintain the systemic blood pressure in hypotensive patients with sepsis. A rare complication in this setting is the development of a marked natriuresis and diuresis with the urine volume occasionally exceeding 300 to 500 mL/hour despite reduced kidney perfusion [<a href="#rid18">18,19</a>]. The natriuresis presumably reflects the normal inhibitory effect of dopamine on sodium reabsorption; why it may be dramatically enhanced in some septic patients is not clear.</p><p class="headingAnchor" id="H9"><span class="h2">Resistant edema</span><span class="headingEndMark"> — </span>The role of low-dose <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> in patients with diuretic-resistant edema is unclear. The best data come from the Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study in which 241 patients with acute heart failure and kidney dysfunction (estimated glomerular filtration rate [eGFR] of 15 to 60 mL/min/1.73 m<sup>2</sup>) were randomly assigned to receive dopamine (2 microg/kg/min) or placebo; all patients received diuretic therapy [<a href="#rid4">4</a>]. Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (8524 versus 8296 mL) or on kidney function measured by cystatin C level (0.12 versus 0.11) [<a href="#rid4">4</a>].</p><p>In a post-hoc analysis of the ROSE study, the response to <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> was found to differ according to ejection fraction [<a href="#rid5">5</a>]. Dopamine-enhanced urine volume and sodium excretion were greater among those with reduced ejection fractions (ie, ≤40 percent) than among those with preserved ejection fraction (ie, &gt;40 percent). These post-hoc findings from the ROSE study were explored in two subsequent trials of patients with acute heart failure and preserved ejection fraction (HFpEF):</p><p class="bulletIndent1"><span class="glyph">●</span>The Diuretics and <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> in Heart Failure with Preserved Ejection Fraction (ROPA-DOP) trial assigned 90 patients with HFpEF to intermittent <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>, continuous furosemide plus low-dose dopamine, or intermittent furosemide plus low-dose dopamine [<a href="#rid20">20</a>]. Compared with intermittent furosemide, the continuous furosemide strategy led to an 11 percent greater rise in serum creatinine at 72 hours and a 25 percent greater relative risk of acute kidney injury (defined as a serum creatinine increase &gt;0.4 mg/dL within 72 hours). The addition of low-dose dopamine did not appear to modify the risk of a diuretic-induced rise in serum creatinine, and there were no significant differences between strategy arms in length of stay or total urine output. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, treatment with diuretics plus low-dose <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> was compared with diuretics alone in 100 patients with HFpEF [<a href="#rid21">21</a>]. Low-dose dopamine failed to prevent worsening of estimated GFR from admission to discharge. However, patients in the dopamine arm lost more weight (-1.4 versus 0.9 kg), had a larger diuresis (2072 versus 1690 mL/day), and had shorter hospital stays (3.9 versus 4.8 days). However, mean diuretic doses were relatively modest: 178 and 175 mg of intravenous <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> daily and 28 and 27 mg of <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> daily in the two groups. There were no differences in rehospitalization or mortality during a six-month follow-up.  </p><p></p><p>Given the conflicting data and the lack of a "kidney-protective" benefit of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a>, we would not advocate its use to achieve an enhanced diuresis.</p><p class="headingAnchor" id="H10"><span class="h1">DOPAMINE A-1 AGONISTS</span><span class="headingEndMark"> — </span>It is possible that the renal therapeutic actions of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> are obviated because of its nonselective effects upon multiple dopaminergic and adrenergic receptors. For the treatment of acute kidney failure, an ideal agent would selectively activate the renal dopamine A-1 receptor without affecting additional receptors, thereby lowering renal vascular resistance, enhancing natriuresis, and increasing urinary output [<a href="#rid22">22</a>]. Although not ideal, <a class="drug drug_general" data-topicid="8629" href="/d/drug information/8629.html" rel="external">fenoldopam</a> is a relatively selective dopamine A-1 receptor agonist that increases sodium excretion and renal blood flow in normal and hypertensive humans [<a href="#rid23">23</a>].</p><p>Studies that have examined the utility of <a class="drug drug_general" data-topicid="8629" href="/d/drug information/8629.html" rel="external">fenoldopam</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H1812836"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> is synthesized within the proximal tubule and is also released from renal nerves that contain dopamine. Circulating and locally formed dopamine can affect both sodium excretion and renal hemodynamics (see <a class="local">'Introduction'</a> above and <a class="local">'Renal actions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> is a natriuretic hormone, increasing sodium excretion by diminishing reabsorption in the proximal tubule and collecting tubule. (See <a class="local">'Natriuresis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When infused in low doses (0.5 to 3 mcg/kg per minute), <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> dilates the interlobular arteries and both the afferent (preglomerular) and efferent (postglomerular) arterioles. The net effect is a relatively large increase in renal blood flow with a lesser or no elevation in glomerular filtration rate (GFR). At higher concentrations (above 5 mcg/kg per minute), dopamine induces renal vasoconstriction. (See <a class="local">'Vascular effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose (ie, "renal dose") <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> has been used to increase the urine output and to preserve kidney function in oliguric patients at risk for ischemic acute tubular necrosis (ATN). However, such therapy is ineffective and may cause harm, and therefore should <strong>not</strong> be used. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis", section on 'Experimental and unproven measures for the prevention of ischemic ATN'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It has been proposed that the natriuretic and renal vasodilator activity of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> can be used to potentiate the effect of diuretics in patients with resistant edema. However, limited data suggest that dopamine is not beneficial in these patients. (See <a class="local">'Resistant edema'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data suggest that <a class="drug drug_general" data-topicid="8629" href="/d/drug information/8629.html" rel="external">fenoldopam</a>, a selective <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> A-1 receptor agonist, may be beneficial in the prevention or treatment of acute kidney injury. These data, and corresponding recommendations, are discussed separately.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 50:4.</a></li><li><a class="nounderline abstract_t">Seri I, Kone BC, Gullans SR, et al. Influence of Na+ intake on dopamine-induced inhibition of renal cortical Na(+)-K(+)-ATPase. Am J Physiol 1990; 258:F52.</a></li><li><a class="nounderline abstract_t">Carey RM. Theodore Cooper Lecture: Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension 2001; 38:297.</a></li><li><a class="nounderline abstract_t">Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533.</a></li><li><a class="nounderline abstract_t">Wan SH, Stevens SR, Borlaug BA, et al. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 2016; 9.</a></li><li><a class="nounderline abstract_t">Steinhausen M, Weis S, Fleming J, et al. Responses of in vivo renal microvessels to dopamine. Kidney Int 1986; 30:361.</a></li><li><a class="nounderline abstract_t">Olsen NV, Hansen JM, Ladefoged SD, et al. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin Sci (Lond) 1990; 78:503.</a></li><li><a class="nounderline abstract_t">Felder CC, Campbell T, Albrecht F, Jose PA. Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol 1990; 259:F297.</a></li><li><a class="nounderline abstract_t">Krishna GG, Danovitch GM, Beck FW, Sowers JR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med 1985; 105:214.</a></li><li><a class="nounderline abstract_t">Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89:1496.</a></li><li><a class="nounderline abstract_t">Natarajan AR, Eisner GM, Armando I, et al. The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans. J Am Soc Nephrol 2016; 27:265.</a></li><li><a class="nounderline abstract_t">Nandkeolyar S, Ryu R, Mohammad A, et al. A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure. J Cardiovasc Pharmacol 2021; 78:336.</a></li><li><a class="nounderline abstract_t">Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med 1991; 115:153.</a></li><li><a class="nounderline abstract_t">Lauschke A, Teichgräber UK, Frei U, Eckardt KU. 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69:1669.</a></li><li><a class="nounderline abstract_t">Thompson BT, Cockrill BA. Renal-dose dopamine: a siren song? Lancet 1994; 344:7.</a></li><li><a class="nounderline abstract_t">Alexander RW, Gill JR Jr, Yamabe H, et al. Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man. J Clin Invest 1974; 54:194.</a></li><li><a class="nounderline abstract_t">Hansell P, Fasching A. The effect of dopamine receptor blockade on natriuresis is dependent on the degree of hypervolemia. Kidney Int 1991; 39:253.</a></li><li><a class="nounderline abstract_t">Flis RS, Scoblionco DP, Bastl CP, Popovtzer MM. Dopamine-related polyuria in patients with gram-negative infection. Arch Intern Med 1977; 137:1547.</a></li><li><a class="nounderline abstract_t">Polansky D, Eberhard N, McGrath R. Dopamine and polyuria. Ann Intern Med 1987; 107:941.</a></li><li><a class="nounderline abstract_t">Sharma K, Vaishnav J, Kalathiya R, et al. Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. JACC Heart Fail 2018; 6:859.</a></li><li><a class="nounderline abstract_t">El-Moneum MS, Elshaier A, Elkeshk E, and Bendary A. Low dose dopamine in prevention of GFR deterioration in acute. J Cardiovasc Dis Res 2021; 1:188.</a></li><li><a class="nounderline abstract_t">Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998; 31:743.</a></li><li><a class="nounderline abstract_t">Allison NL, Dubb JW, Ziemniak JA, et al. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987; 41:282.</a></li></ol></div><div id="topicVersionRevision">Topic 2368 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8807566" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154126" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Influence of Na+ intake on dopamine-induced inhibition of renal cortical Na(+)-K(+)-ATPase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566894" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Theodore Cooper Lecture: Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27512103" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3023735" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Responses of in vivo renal microvessels to dopamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2162278" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1974737" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3973460" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dopaminergic mediation of the natriuretic response to volume expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349027" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25977313" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34117179" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2058863" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal-dose dopamine: fact and fiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572117" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912346" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal-dose dopamine: a siren song?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4600048" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002639" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effect of dopamine receptor blockade on natriuresis is dependent on the degree of hypervolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921441" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dopamine-related polyuria in patients with gram-negative infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688686" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dopamine and polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098962" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Low dose dopamine in prevention of GFR deterioration in acute</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590183" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Potential of dopamine A-1 agonists in the management of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2880688" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
